Anticoagulation plus tocilizumab for cerebral venous thrombosis
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a combination of blood thinners (anticoagulation) and a drug called tocilizumab, which targets inflammation, to treat acute cerebral venous thrombosis (a blood clot in a vein in the brain). It aims to see if this combined treatment improves recovery and reduces complications compared to blood thinners alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a confirmed blood clot in a vein in the brain (cerebral venous thrombosis) seen on an imaging test.
- Your symptoms started within the last 4 weeks (14 days before or after the start of the trial).
- You are not currently taking immunosuppressive drugs (like certain steroids or biologics) and do not have an active infection or immune disease.
- You do not have severe kidney or liver problems, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a medication called batroxobin to standard blood thinners can help treat blood clots in the veins of the brain better than blood thinners alone. It is for people who have been diagnosed in the last month and are not at high risk for bleeding.
This trial tests two blood thinner medicines, edoxaban and rivaroxaban, in Chinese patients with a blood clot in a brain vein (cerebral venous thrombosis). It aims to see if these medicines are safe and work well.
This trial tests whether taking blood-thinning pills (called DOACs) after initial treatment can safely treat blood clots in the veins of the brain. You may be able to join if you recently had this condition and start the pills within the first two weeks of treatment.
This study looks at people with cerebral venous thrombosis who were treated with blood thinners taken by mouth (or started within the first 30 days). It uses observational data to understand how these treatments are used and what outcomes may follow.
This trial tests adding the anti-clotting drug tirofiban to standard clot removal for people who have a stroke due to a narrowed artery in the brain. The goal is to see if this combination improves outcomes without raising bleeding risk.
This trial tests a clot-busting drug (rhTNK-tPA) to remove blood from the ventricles (fluid spaces deep in the brain) after a spontaneous brain bleed. It may help patients whose ventricles are blocked by a large clot, reducing pressure and improving recovery.
Hear when a new Cerebral Venous Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.